enzh-TWfrdeitjaptrues

Highlights and Consensus Panel Reports from the 11th International Workshop on Waldenstrom's Macroglobulinemia.

Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care:

https://www.sciencedirect.com/science/article/pii/S0037196323000380

Report of Consensus Panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on Management of Symptomatic, Treatment-Naïve Patients:
https://www.sciencedirect.com/science/article/abs/pii/S0037196323000264

Report of Consensus Panel 2 from the 11th International Workshop on Waldenström's Macroglobulinemia on the Management of Relapsed or Refractory WM Patients:
https://www.sciencedirect.com/science/article/abs/pii/S0037196323000252

Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia on Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia:
https://www.sciencedirect.com/science/article/pii/S0037196323000276#bib0016

Report of Consensus Panel 4 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on Diagnostic and Response Criteria:
https://www.sciencedirect.com/science/article/pii/S0037196323000379

Report of Consensus Panel 5 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on COVID-19 Prophylaxis and Management:
https://www.sciencedirect.com/science/article/pii/S0037196323000240

Report of Consensus Panel 6 from the 11th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis:
https://www.sciencedirect.com/science/article/abs/pii/S0037196323000227

Report of Consensus Panel 7 from the 11th International Workshop on Waldenström Macroglobulinemia on Priorities for Novel Clinical Trials.: Clinical Trial Priorities for WM:
https://www.sciencedirect.com/science/article/abs/pii/S0037196323000239